A phase I clinical trial confirmed that a dual-action inhibitor linsitinib (OSI-906) that targets IGF1R and insulin receptor (IR) at the same time has good antitumor activity in vivo [148]; unfortunately, before reaching the maximum tolerated dose, the OSI-906 plus mTOR inhibitor everolimus regimen has not manifested clinical efficacy when being used to treat refractory CRC [149]. This evidence concerns the gene INSR and colorectal carcinoma.